Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample

International Clinical Psychopharmacology

Volumn 15, Issue 5, 2000, Pages 245-255

  Hamilton, S H ^a   Edgell, E T ^a   Revicki, D A ^a   Breier, A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Europe; Hospitalization; Olanzapine; Outcomes; Reinteg ration; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EUROPE; FEMALE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIALIZATION; TREATMENT OUTCOME; WORK;

EID: 0033846290     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015050-00001     Document Type: Article

References (43)

1. Pharmacologic treatment
2. Olanzapine vs. placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
3. Recent advances in the pharmacotherapy of schizophrenia
4. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome
5. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
6. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis
7. Schizophrenia
8. The varied outcomes of schizophrenia
9. Antipsychotic drugs
10. Conventional antipsychotic medication for schizophrenia
11. Clozapine: A review of its pharmacological properties and therapeutic use in schizophrenia
12. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American Double-Blind Trial
13. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial
14. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome
15. Negative symptoms at discharge and outcome in schizophrenia
16. Schizophrenia
17. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
18. Schizophrenic disorders
19. Economic outcomes and costs in the treatment of schizophrenia. Personal Social Services Research Unit, London School of Economics and Political Science, United Kingdom
20. Evaluating outcomes of treatments for persons with psychotic disorders
21. Convergent validation of quality of life assessments for persons with severe mental illness
22. Maximizing schizophrenia treatment outcomes: A model for reintegration
23. Reintegration studies: Maximizing outcomes
24. Issues of reintegration and rehabilitation in schizophrenia
25. Management of schizophrenia
26. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
27. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Quality of life and clinical outcomes of a randomized clinical trial
28. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
29. The Scottish first episode schizophrenia study VIII. Five-year follow-up: Clinical and psychosocial findings
30. The natural history of schizophrenia: A five year follow up study of outcome and prediction in a representative sample of schizophrenics
31. The prediction of outcome in schizophrenia II. Relationships between predictor and outcome variables: A report from the WHO International Pilot Study of Schizophrenia
32. Neuroleptic-induced extrapyramidal reactions: Classification, description, and diagnosis
33. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial
34. Cost of relapse in schizophrenia
35. Anchoring the BPRS: An aid to improved reliability